Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease

Clinical Immunology

Volumn 147, Issue 2, 2013, Pages 122-128

  Kawai, Toshinao ^a   Watanabe, Nobuyuki ^a   Yokoyama, Midori ^a   Arai, Katsuhiro ^a   Oana, Shinji ^a   Harayama, Shizuko ^a,b   Yasui, Kozo ^c   Oh Ishi, Tsutomu ^d   Onodera, Masafumi ^a  

^a NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HIROSHIMA CITY HOSPITAL   (Japan)

^d SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

Chronic granulomatous disease; Cytokine; Inflammatory bowel disease; Reactive oxygen species; Thalidomide

Indexed keywords

ADENOSINE TRIPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; CASPASE 1; CELLS, CULTURED; CHILD, PRESCHOOL; CYTOKINES; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; MYCOBACTERIUM BOVIS; NF-KAPPA B; PULMONARY ASPERGILLOSIS; THALIDOMIDE; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876346636     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.03.004     Document Type: Article

References (24)

1. Meissner F., Seger R.A., Moshous D., Fischer A., Reichenbach J., Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 2010, 116:1570-1573.
2. Dostert C., Petrilli V., Van Bruggen R., Steele C., Mossman B.T., Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
3. Kawai T., Kusakabe H., Seki A., Kobayashi S., Onodera M. Osteomyelitis due to trimethoprim/sulfamethoxazole-resistant Edwardsiella tarda infection in a patient with X-linked chronic granulomatous disease. Infection 2011, 39:171-173.
4. Marks D.J., Miyagi K., Rahman F.Z., Novelli M., Bloom S.L., Segal A.W. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am. J. Gastroenterol. 2009, 104:117-124.
5. Uzel G., Orange J.S., Poliak N., Marciano B.E., Heller T., Holland S.M. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin. Infect. Dis. 2010, 51:1429-1434.
6. Meierhofer C., Wiedermann C.J. New insights into the pharmacological and toxicological effects of thalidomide. Curr. Opin. Drug Discovery Devel. 2003, 6:92-99.
7. Keller M., Sollberger G., Beer H.D. Thalidomide inhibits activation of caspase-1. J. Immunol. 2009, 183:5593-5599.
8. Eski M., Sahin I., Sengezer M., Serdar M., Ifran A. Thalidomide decreases the plasma levels of IL-1 and TNF following burn injury: is it a new drug for modulation of systemic inflammatory response. Burns 2008, 34:104-108.
9. Sokol H., Suarez F., Meatchi T., Malamut G., Pocidalo M.A., Blanche S., Cellier C., Hermine O. Thalidomide as a treatment for refractory CGD colitis. Am. J. Gastroenterol. 2009, 104:1069.
10. Wallet M.A., Wallet S.M., Guiulfo G., Sleasman J.W., Goodenow M.M. IFNgamma primes macrophages for inflammatory activation by high molecular weight hyaluronan. Cell. Immunol. 2010, 262:84-88.
11. Netea M.G., Nold-Petry C.A., Nold M.F., Joosten L.A., Opitz B., van der Meer J.H., van de Veerdonk F.L., Ferwerda G., Heinhuis B., Devesa I., Funk C.J., Mason R.J., Kullberg B.J., Rubartelli A., van der Meer J.W., Dinarello C.A. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009, 113:2324-2335.
12. van de Veerdonk F.L., Smeekens S.P., Joosten L.A., Kullberg B.J., Dinarello C.A., van der Meer J.W., Netea M.G. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3030-3033.
13. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
14. Liobikas J., Majiene D., Trumbeckaite S., Kursvietiene L., Masteikova R., Kopustinskiene D.M., Savickas A., Bernatoniene J. Uncoupling and antioxidant effects of ursolic acid in isolated rat heart mitochondria. J. Nat. Prod. 2011, 74:1640-1644.
15. Majumdar S., Lamothe B., Aggarwal B.B. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J. Immunol. 2002, 168:2644-2651.
16. Franchi L., Munoz-Planillo R., Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 2012, 13:325-332.
17. Pelegrin P., Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J. 2006, 25:5071-5082.
18. Turner D., Otley A.R., Mack D., Hyams J., de Bruijne J., Uusoue K., Walters T.D., Zachos M., Mamula P., Beaton D.E., Steinhart A.H., Griffiths A.M. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007, 133:423-432.
19. Yasui K., Uchida N., Akazawa Y., Nakamura S., Minami I., Amano Y., Yamazaki T. Thalidomide for treatment of intestinal involvement of juvenile-onset Behcet disease. Inflamm. Bowel. Dis. 2008, 14:396-400.
20. Malik S., Wong S.C., Bishop J., Hassan K., McGrogan P., Ahmed S.F., Russell R.K. Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J. Pediatr. Gastroenterol. Nutr. 2011, 52:31-37.
21. Olsen T., Goll R., Cui G., Christiansen I., Florholmen J. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine 2009, 46:222-227.
22. Hatanaka E., Carvalho B.T., Condino-Neto A., Campa A. Hyperresponsiveness of neutrophils from gp 91phox deficient patients to lipopolysaccharide and serum amyloid A. Immunol. Lett. 2004, 94:43-46.
23. Segal B.H., Han W., Bushey J.J., Joo M., Bhatti Z., Feminella J., Dennis C.G., Vethanayagam R.R., Yull F.E., Capitano M., Wallace P.K., Minderman H., Christman J.W., Sporn M.B., Chan J., Vinh D.C., Holland S.M., Romani L.R., Gaffen S.L., Freeman M.L., Blackwell T.S. NADPH oxidase limits innate immune responses in the lungs in mice. PLoS One 2010, 5:e9631.
24. Keifer J.A., Guttridge D.C., Ashburner B.P., Baldwin A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem. 2001, 276:22382-22387.